A 58-year-old woman with a history of myocardial infarction presents with recurrent ventricular ectopy. Her physician is comparing propranolol (Class II) and sotalol (Class III with beta-blocking properties) for rhythm control. Which finding would best distinguish the primary electrophysiological effect of propranolol from that of sotalol?

Explanation

## Distinguishing Class II (Beta-Blockers) from Class III Antiarrhythmics with Beta-Blocking Properties ### The Dual Nature of Sotalol **Key Point:** Sotalol is a **hybrid antiarrhythmic** with both Class II (beta-blocking) and Class III (potassium channel blockade) properties. Propranolol is a **pure Class II** agent. The distinguishing feature is the **presence or absence of Class III activity**. | Property | Propranolol (Class II) | Sotalol (Class II + III) | |----------|----------------------|------------------------| | **Beta-blockade** | Yes (primary effect) | Yes (secondary effect) | | **APD prolongation** | No | Yes | | **QT interval** | Minimal change | Marked prolongation | | **Potassium channel blockade** | No | Yes (primary effect) | | **Effect on SA/AV nodes** | Slowed conduction | Slowed conduction + increased refractoriness | ### Class II Mechanism: Propranolol 1. **Beta-adrenergic antagonism** — blocks β~1~ and β~2~ receptors 2. **Effect on nodal tissue:** Slows SA nodal firing and AV nodal conduction 3. **Effect on APD:** Minimal or no prolongation 4. **ECG finding:** Bradycardia, PR prolongation, minimal QT change ### Class III Mechanism: Sotalol's Unique Advantage 1. **Potassium channel blockade** — inhibits delayed rectifier K^+^ current (I~Kr~) 2. **Effect on APD:** Marked prolongation across all cardiac tissue 3. **Effect on QT:** Significant QT prolongation 4. **Combined effect:** Both nodal slowing (Class II) AND increased refractoriness (Class III) **High-Yield:** Sotalol's **Class III activity makes it more effective** for ventricular arrhythmias than pure beta-blockers, but it carries **increased torsades de pointes risk** due to QT prolongation. **Mnemonic:** **"SOTALOL = SOdium-sparing, Torsades-prone, APD-Lengthening, Oral, Late K^+^ channel blocker"** — helps recall its Class III dominance despite the beta-blocking name. ### Clinical Discrimination ```mermaid flowchart TD A[Antiarrhythmic needed]:::outcome --> B{Structural heart disease?}:::decision B -->|Yes, post-MI| C[Propranolol preferred]:::action B -->|No, or VT/VF risk| D[Sotalol considered]:::action C --> E[Class II only: nodal slowing]:::outcome D --> F[Class II + III: nodal slowing + APD prolongation]:::outcome F --> G{Monitor QTc}:::decision G -->|QTc > 500 ms| H[Risk of torsades]:::urgent ``` **Clinical Pearl:** In post-MI patients with ventricular ectopy, propranolol (Class II only) is safer than sotalol because it lacks the QT-prolonging Class III effect, reducing torsades risk while still providing beta-blockade benefit.